Literature DB >> 17964887

Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review.

Edith H Cup1, Allan J Pieterse, Jessica M Ten Broek-Pastoor, Marten Munneke, Baziel G van Engelen, Henk T Hendricks, Gert J van der Wilt, Rob A Oostendorp.   

Abstract

OBJECTIVE: To summarize and critically appraise the available evidence on exercise therapy and other types of physical therapies for patients with neuromuscular diseases (NMD). DATA SOURCES: Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, Medline, CINAHL, EMBASE (Rehabilitation and Physical Medicine), and reference lists of reviews and articles. STUDY SELECTION: Randomized clinical trials (RCTs), controlled clinical trials (CCTs), and other designs were included. Study participants had to have any of the following types of NMD: motoneuron diseases, disorders of the motor nerve roots or peripheral nerves, neuromuscular transmission disorders, or muscle diseases. All types of exercise therapy and other physical therapy modalities were included. Outcome measures had to be at the level of body functions, activities, or participation according to the definitions of the International Classification of Functioning, Disability and Health (ICF). DATA EXTRACTION: Two reviewers independently decided on inclusion or exclusion of articles and rated the methodologic quality of the studies included. All RCTs, CCTs, and other designs only if of sufficient methodologic quality were included in a best evidence synthesis. A level of evidence was attributed for each subgroup of NMD and each type of intervention. DATA SYNTHESIS: Initially 58 studies were included: 12 RCTs, 5 CCTs, and 41 other designs. After methodologic assessment, 19 other designs were excluded from further analysis. There is level II evidence ("likely to be effective") for strengthening exercises in combination with aerobic exercises for patients with muscle disorders. Level III evidence ("indications of effectiveness") was found for aerobic exercises in patients with muscle disorders and for the combination of muscle strengthening and aerobic exercises in a heterogeneous group of muscle disorders. Finally, there is level III evidence for breathing exercises for patients with myasthenia gravis and for patients with myotonic muscular dystrophy. Adverse effects of exercise therapy were negligible.
CONCLUSIONS: The available evidence is limited, but relevant for clinicians. Future studies should be preferably multicentered, and use an international classification of the variables of exercise therapy and an ICF core set for NMD in order to improve comparability of results.

Entities:  

Mesh:

Year:  2007        PMID: 17964887     DOI: 10.1016/j.apmr.2007.07.024

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  47 in total

1.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Authors:  Bruno Kusznir Vitturi; Alexandre In Han Kim; Lucas Pari Mitre; Ada Pellegrinelli; Berenice Cataldo Oliveira Valerio
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

Review 2.  Spinal and Bulbar Muscular Atrophy.

Authors:  Christopher Grunseich; Kenneth H Fischbeck
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

3.  Childhood Activity on Progression in Limb Girdle Muscular Dystrophy 2I.

Authors:  Brianna N Brun; Shelley R H Mockler; Katie M Laubscher; Carrie M Stephan; Julia A Collison; M Bridget Zimmerman; Katherine D Mathews
Journal:  J Child Neurol       Date:  2016-11-22       Impact factor: 1.987

Review 4.  Strength training and aerobic exercise training for muscle disease.

Authors:  Nicoline Bm Voet; Elly L van der Kooi; Baziel Gm van Engelen; Alexander Ch Geurts
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

5.  Effects of Physical Rehabilitation in Patients with Spinocerebellar Ataxia Type 7.

Authors:  Karla Tercero-Pérez; Hernán Cortés; Yessica Torres-Ramos; Roberto Rodríguez-Labrada; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Nelson Pérez-González; Rigoberto González-Piña; Norberto Leyva-García; Bulmaro Cisneros; Luis Velázquez-Pérez; Jonathan J Magaña
Journal:  Cerebellum       Date:  2019-06       Impact factor: 3.847

6.  Lambert-eaton myasthenic syndrome.

Authors:  Maria B Weimer; Joaquin Wong
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

7.  [Myasthenia gravis].

Authors:  J Schodrowski; M Seipelt; I Adibi-Sedeh; C Eienbröker; B Tackenberg
Journal:  Internist (Berl)       Date:  2016-04       Impact factor: 0.743

8.  Effect of skilled and unskilled training on nerve regeneration and functional recovery.

Authors:  A S Pagnussat; S M Michaelsen; M Achaval; J Ilha; E E S Hermel; F P Back; C A Netto
Journal:  Braz J Med Biol Res       Date:  2012-05-17       Impact factor: 2.590

9.  Exercise therapy and cognitive behavioural therapy to improve fatigue, daily activity performance and quality of life in postpoliomyelitis syndrome: the protocol of the FACTS-2-PPS trial.

Authors:  Fieke S Koopman; Anita Beelen; Karin H Gerrits; Gijs Bleijenberg; Tineke A Abma; Marianne de Visser; Frans Nollet
Journal:  BMC Neurol       Date:  2010-01-18       Impact factor: 2.474

10.  Gait Difficulties and Postural Instability in Adrenoleukodystrophy.

Authors:  Neha P Godbole; Reza Sadjadi; Madeline A DeBono; Natalie R Grant; Daniel C Kelly; Peter F James; Christopher D Stephen; M David Balkwill; Richard F Lewis; Florian S Eichler
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.